Our multidisciplinary team of chemists and biologists work closely with customers to design, synthesize and optimize compounds for targets and assays, leading to rapid identification of potential drug candidates. We have a strong track record in successfully driving several pharmaceutical hit-to-lead projects in the therapeutic areas of Oncology, Fibrosis, Pain, Inflammation, Cardiovascular and Metabolic Diseases. As responsive and reliable partners, customers view us as an extension of their R&D teams, augmenting in-house expertise and capabilities.
Hit Generation & Validation
Aragen medicinal chemists use high-throughput screening and literature analysis to identify valuable starting points for discovery programs. Our capabilities include:
Hit-to-Lead Identification
With evaluations, gap analyses and corrections to the identified hit series, we focus on identifying promising lead compounds through:
Lead Optimization
Further optimizations address structure activity relationship (SAR) and structure property relationship (SPR) evaluation criteria to provide customers with a suitable preclinical candidate. Capabilities at this stage include:
Ensuring the quality, reliability and data accuracy of synthesized compounds, prior to biological testing in the drug discovery process.
Earning the complete trust and confidence of our customers.
